Daunorubicin 90mg/m2 in acute myeloid leukemia induction: increased toxicity in young patients
The combination of an anthracycline and cytosine arabinoside has been the standard induction therapy for acute myeloid leukemia (AML) for more than three decades. The clinical benefit of intensification of daunorubicin dose to 90mg/m2 has been supported by randomized trials. Based on these promising results, in 2010 we changed our induction protocol of AML, increasing the dose of daunorubicin. Herein, we retrospectively analyzed the treatment outcome of patients treated with high-dose daunorubicin (90mg/m2 days 1-3) and cytosine arabinoside (200mg/m2/day continuous infusion days 1-7) compared with patients receiving 45-60mg/m2 of daunorubicin.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Rodrigo Portugal, Renata Lyrio, Monique Loureiro, K átia Urago, Johny Bard, Aline Borchardt, Márcia Garnica, Márcio Nucci Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Lymphoma | Middle East Health | Myeloma | Study | Toxicology